Literature DB >> 15740719

Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.

Gerald Gimpl1, Rolf Postina, Falk Fahrenholz, Torsten Reinheimer.   

Abstract

We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin. For this purpose, chimeric 'gain-in function' oxytocin/vasopressin V2 receptors were expressed in COS-7 cells. These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996. Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor. J. Biol. Chem. 271, 31593-31601). In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin, carbetocin, and atosiban. The binding profiles for the agonists oxytocin and carbetocin were found to be similar. For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the oxytocin receptor. For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor. In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the vasopressin V2 receptor. The binding domain of barusiban differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies. Overall, the data supported the concept of a central pocket site within the oxytocin receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740719     DOI: 10.1016/j.ejphar.2005.01.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes.

Authors:  Marta Busnelli; Aude Saulière; Maurice Manning; Michel Bouvier; Celine Galés; Bice Chini
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test.

Authors:  Stella Chaviaras; Plato Mak; David Ralph; Lalitha Krishnan; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 3.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

Review 4.  Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms.

Authors:  Ryan W Mull; Anthony Harrington; Lucia A Sanchez; Yftah Tal-Gan
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

5.  Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation.

Authors:  I Passoni; M Leonzino; V Gigliucci; B Chini; M Busnelli
Journal:  J Neuroendocrinol       Date:  2016-04       Impact factor: 3.627

6.  Oxytocin/vasopressin-like peptide inotocin regulates cuticular hydrocarbon synthesis and water balancing in ants.

Authors:  Akiko Koto; Naoto Motoyama; Hiroki Tahara; Sean McGregor; Minoru Moriyama; Takayoshi Okabe; Masayuki Miura; Laurent Keller
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-06       Impact factor: 11.205

7.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

Review 8.  Oxytocin in metabolic homeostasis: implications for obesity and diabetes management.

Authors:  C Ding; M K-S Leow; F Magkos
Journal:  Obes Rev       Date:  2018-09-25       Impact factor: 9.213

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.